Tezspire – BiotechReality – Information Intelligence System for Biopharma

AstraZeneca Tezspire, also known as tezepelumab, has received approval from the European Commission to treat adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). For patients who have not responded well to conventional treatments like systemic corticosteroids and surgery, this ground-breaking ruling provides a new therapeutic option. Tezspire is currently approved for use in conjunction with intranasal corticosteroids as an adjuvant treatment. For those who suffer from this difficult and frequently incapacitating condition, the approval marks a significant milestone. Persistent sinus and nasal passage inflammation, which results in the development of benign, teardrop-shaped polyps, is a characteristic of CRSwNP. Severe nasal congestion, diminished or absent smell, and facial pressure or pain are all possible side effects of these polyps. In Europe, we know that nearly half of patients with chronic rhinosinusitis with nasal polyps remain uncontrolled despite treatment with standard of care, which is why today’s approval of Tezspire is such an important step forward in this challenging disease. This approval broadens Tezspire’s benefits beyond severe asthma and reinforces Tezspire’s innovative mechanism of action that targets thymic stromal lymphopoietin (TSLP), uniquely addressing epithelial-driven inflammation at its source. Ruud Dobber Read More: AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide The positive results from a clinical trial that showed Tezspire's effectiveness in minimising nasal congestion and shrinking nasal polyps served as the basis for the approval. Additionally, it was demonstrated that the treatment significantly reduced the use of systemic corticosteroids, which can have long-term side effects, and almost completely eliminated the need for surgery. Tezspire was previously approved for severe asthma, but its indications have been expanded with its approval for CRSwNP. The drug's potential to treat a variety of inflammatory conditions is highlighted by this new application. The European Commission has now formally adopted the drug, which was previously approved by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). All member states of the European Union are covered by this approval. Information: AstraZeneca Last Modified:

Tag: Tezspire

AstraZeneca’s Tezspire Gains EU Approval for Nasal Polyps, Offering New Hope for Patients

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment